Curis, Debiopharm Start Phase I Study Of Debio 0932 With Everolimus – NASDAQ
Curis, Debiopharm Start Phase I Study Of Debio 0932 With EverolimusNASDAQ(RTTNews.com) – Curis, Inc.( CRIS ), and Debiopharm Group Tuesday announced the start of a Phase I dose-finding study of Debio 0932, a heat shock protein 90 inhibitor in combinati…
